Gilead Sciences, Inc. (NASDAQ: GILD) news summary for the past 24–36 hours:
Positive Sentiment:
Gilead partnered with singer Tamar Braxton to raise awareness of HIV prevention via its PrEP program, boosting the company’s public profile and potential uptake of its preventive therapies.
Tamar Braxton Is Raising Awareness About The Power Of PrEP Under Her New Partnership With Gilead Sciences
Positive Sentiment:
An updated study on sacituzumab govitecan highlighted new data and market implications for Gilead’s cancer‐targeting antibody-drug conjugate, underlining potential revenue upside if trial outcomes remain strong.
Gilead Sciences’ New Study on Sacituzumab Govitecan: Market Implications and Study Insights
Positive Sentiment:
Leerink Partnrs raised its Q3 2025 EPS estimate for Gilead to $2.37 from $2.26, reflecting improved near-term earnings expectations.
Leerink Partnrs Raises Q3 2025 EPS Estimate for Gilead Sciences
Neutral Sentiment:
A new HIV 7MM drug forecast report projects the market to reach $32.1 billion by 2033, with Gilead poised to remain the leading player—underscoring its entrenched HIV franchise.
Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033
Neutral Sentiment:
Gilead has been flagged by Zacks.com as one of the most-watched medical stocks, reflecting heightened investor interest but no direct catalyst reported.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention
Neutral Sentiment:
Another Zacks article on medical stocks mentioned Gilead in a broader earnings-beat screen, but without company-specific forecasts or drivers.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Negative Sentiment:
Leerink Partnrs cut its Q2 2025 EPS forecast for Gilead to $1.91 from $2.25, signaling softer near-term earnings expectations.
Gilead Sciences Q2 EPS Estimate Lowered by Leerink Partnrs
Negative Sentiment:
Pomerantz LLP launched an investor investigation into Gilead over undisclosed claims, introducing potential legal and financial risk.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Negative Sentiment:
Gilead’s CFO, Andrew Dickinson, sold 2,500 shares for about $277,575, reducing his stake by 1.5%, which may raise governance or insider-confidence concerns.
Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $277,575.00 in Stock
Posted 1+ days ago
AI Generated. May Contain Errors.